Clinical trials report that the inhibition of PDL1 interaction with programmed cell death receptors (PD1), expressing on various types of immune cells (including antigen presenting cells, effector T cells, natural killer cells (NK), thymocytes, myeloid cells), leads to durable tumor control by the immune system and the suppression of different types of cancer [7-10]. This evidence concerns the gene CD274 and neoplasm.